Absence of methamphetamine-induced conditioned place preference in weaver mutant mice.
Animals
Central Nervous System Stimulants
/ administration & dosage
Conditioning, Classical
/ drug effects
Dopamine
/ metabolism
Dopamine Uptake Inhibitors
/ administration & dosage
Methamphetamine
/ administration & dosage
Mice
Mice, Inbred C3H
Mice, Neurologic Mutants
Microdialysis
/ methods
Mutation
/ genetics
Nucleus Accumbens
/ drug effects
CPP
GIRK
methamphetamine
reward
weaver mutant mice
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
18
06
2020
revised:
14
07
2020
accepted:
14
07
2020
pubmed:
20
8
2020
medline:
8
9
2021
entrez:
20
8
2020
Statut:
ppublish
Résumé
G protein-activated inwardly rectifying potassium (GIRK) channels are related to rewarding effects of addictive drugs. The GIRK2 subunit is thought to play key roles in the reward system. Weaver mutant mice exhibit abnormal GIRK2 function and different behaviors that are caused by several addictive substances compared with wild-type mice. However, mechanisms of reward-related alterations in weaver mutant mice remain unclear. The present study investigated changes in the rewarding effects of methamphetamine (METH) in weaver mutant mice. The rewarding effects of METH (4.0 mg/kg) were investigated using the conditioned place preference (CPP) paradigm. Extracellular dopamine level in the nucleus accumbens (NAc) was measured by in vivo microdialysis. To identify brain regions that were associated with these changes in rewarding effects, METH-induced alterations of Fos expression were investigated by immunohistochemical analysis. Weaver mutant mice exhibited a significant decrease in METH-induced CPP and dopamine release in the NAc. Methamphetamine significantly increased Fos expression in the posterior NAc (pNAc) shell in wild-type but not in weaver mutant mice. Methamphetamine did not induce rewarding effects in weaver mutant mice. The pNAc shell exhibited a significant difference in neuronal activity between wild-type and weaver mutant mice. The present results suggest that the absence of METH-induced CPP in weaver mutant mice is probably related to an innate reduction of dopamine and decreased neural activity in the pNAc shell that is partially attributable to the change of GIRK channel function. GIRK channels, especially those containing the GIRK2 subunit, appear to be involved in METH dependence.
Identifiants
pubmed: 32812711
doi: 10.1002/npr2.12130
pmc: PMC7722684
doi:
Substances chimiques
Central Nervous System Stimulants
0
Dopamine Uptake Inhibitors
0
Methamphetamine
44RAL3456C
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-331Informations de copyright
© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsycho Pharmacology.
Références
Prog Neurobiol. 1998 Dec;56(6):613-72
pubmed: 9871940
J Neurosci. 1982 Mar;2(3):376-80
pubmed: 7062116
J Neurosci. 2008 Jul 2;28(27):6950-9
pubmed: 18596169
Front Behav Neurosci. 2019 Nov 29;13:262
pubmed: 31849622
Neuropsychopharmacol Rep. 2019 Jun;39(2):90-99
pubmed: 30756527
PLoS One. 2020 Jan 10;15(1):e0227644
pubmed: 31923269
Neuropsychopharmacol Rep. 2020 Dec;40(4):324-331
pubmed: 32812711
Neurosci Res. 2000 Sep;38(1):113-6
pubmed: 10997585
Trends Pharmacol Sci. 2017 Apr;38(4):378-392
pubmed: 28188005
Nat Neurosci. 1999 Dec;2(12):1091-7
pubmed: 10570486
Int Rev Neurobiol. 2015;123:239-77
pubmed: 26422987
J Neurosci. 2011 Apr 20;31(16):6001-7
pubmed: 21508225
Neurochem Res. 1999 Nov;24(11):1455-70
pubmed: 10555787
Neuropsychopharmacol Rep. 2018 Mar;38(1):9-17
pubmed: 30106266
Eur J Neurosci. 2008 Jul;28(2):342-52
pubmed: 18702705
Curr Neuropharmacol. 2011 Mar;9(1):68-72
pubmed: 21886565
J Biol Chem. 1995 Dec 1;270(48):28660-7
pubmed: 7499385
Nat Rev Neurosci. 2010 May;11(5):301-15
pubmed: 20389305
Neuropsychopharmacology. 2003 May;28(5):932-8
pubmed: 12637950
Nat Genet. 1995 Oct;11(2):126-9
pubmed: 7550338
Neuron. 2012 Mar 8;73(5):978-89
pubmed: 22405207
Neurosci Res. 2002 Oct;44(2):121-131
pubmed: 12354627
Neuron. 2011 Feb 24;69(4):650-63
pubmed: 21338877
J Pharmacol Exp Ther. 2001 Aug;298(2):521-30
pubmed: 11454913
Nat Neurosci. 2007 Aug;10(8):1020-8
pubmed: 17603481
Neuropsychopharmacology. 2006 Mar;31(3):516-24
pubmed: 16123769
Jpn J Pharmacol. 1986 Jun;41(2):147-54
pubmed: 3091891
Life Sci. 1999;64(12):PL151-6
pubmed: 10210291